ArticleClinical pharmacology and therapeutics2023
Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom.
Article in Clinical pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Mitragynine and 7-hydroxy-mitragyine plasma pharmacokinetics in humans after single and 15 multiple oral kratom extract doses.Journal of analytical toxicology · 2026Article
- Article
- A Review of Kratom Product Evolution and Its Associated Health Outcomes.Substance abuse and rehabilitation · 2026Review
- The Impact of Diverse Kratom Products on Use Patterns, Dependence, and Toxicity.Current psychiatry reports · 2025Review
- Evaluating the drug interactions in kratom usage: clinical application.Expert opinion on drug metabolism & toxicology · 2025Review
- A gut response: Application of human enteroid monolayers to probe the mechanism of the goldenseal-mediated inhibition of metformin intestinal absorption.The Journal of pharmacology and experimental therapeutics · 2025Article
- Exploring the Therapeutic Potential of Mitragynine and Corynoxeine: Kratom-Derived Indole and Oxindole Alkaloids for Pain Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Predicting Natural Product-Drug Interactions with Knowledge Graph Embeddings.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2025Article
- Application of physiologically-based pharmacokinetic modeling to inform dosing decisions for geriatric patients.CPT: pharmacometrics & systems pharmacology · 2024Article
- An in vitro evaluation on metabolism of mitragynine to 9-O-demethylmitragynine.Chemico-biological interactions · 2024Article
- Botanical-induced toxicity: Liver injury and botanical-drug interactions. A report on a society of Toxicology Annual Meeting symposium.Regulatory toxicology and pharmacology : RTP · 2024Article
- Multiple-Dose Pharmacokinetics and Safety of Mitragynine, the Major Alkaloid of Kratom, in Rats.ACS pharmacology & translational science · 2024Article
- Article
- Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats.Pharmaceutics · 2024Article
- Commentary: Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report.Frontiers in psychiatry · 2024Article
- An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations.The Journal of pharmacology and experimental therapeutics · 2023Article
- An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1).Chemico-biological interactions · 2023Article
- Article
- An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.Expert review of clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Oral formulations prepared from the leaves of the kratom (Mitragyna speciosa) plant are increasingly used for their opioid-like effects to self-manage opioid withdrawal and pain. Calls to US poison centers involving kratom exposures increased >50-fold from 2011-2017, one-third of which reported concomitant use of kratom with drugs of abuse. Many of these drugs are eliminated primarily via cytochrome P450 (CYP) 3A and CYP2D6, raising concerns for potential adverse pharmacokinetic kratom-drug interactions. The impact of a single low dose of kratom tea (2 g) on the pharmacokinetics of the CYP3A probe midazolam (2.5 mg) and CYP2D6 probe dextromethorphan (30 mg) were assessed in 12 healthy adult participants after oral administration. Kratom showed no effect on dextromethorphan area under the plasma concentration time-curve (AUC) and maximum concentration (C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.